Methotrexat Accord

Methotrexate, the active ingredient in Methotrexat Accord, is a Antimetabolite (Folate antagonist) presented as a sterile injectable solution for intra‑arterial, intramuscular, and intravenous use. It is employed in the treatment of certain cancers and autoimmune disorders such as leukemia and rheumatoid arthritis.

GNH USA supplies Methotrexat Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Methotrexate is used in several oncologic and autoimmune disease pathways. - Acute lymphoblastic leukemia: reduces malignant lymphoblast proliferation and improves remission rates. - Osteosarcoma: inhibits tumor growth and enhances surgical outcomes. - Rheumatoid arthritis: decreases inflammatory activity and joint damage. - Psoriasis: slows skin cell turnover and reduces plaque formation. - Crohn's disease (off‑label): moderates intestinal inflammation and symptom severity.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting: gastrointestinal discomfort often occurring after administration. - Fatigue: persistent tiredness not relieved by rest. - Alopecia: temporary hair thinning or loss. - Elevated liver enzymes: mild hepatic irritation detected in blood tests. - Oral mucositis: soreness or ulceration of the mouth lining.

Serious or Rare Side Effects: - Myelosuppression: significant reduction in blood cell counts, increasing infection risk. - Pulmonary toxicity: interstitial pneumonitis presenting with cough and shortness of breath. - Severe hepatotoxicity: marked liver injury potentially leading to fibrosis. - Nephrotoxicity: impaired kidney function, especially with high-dose regimens. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Methotrexate requires careful monitoring and specific safety measures. - Renal function: assess creatinine clearance before and during therapy. - Hepatic health: perform baseline and periodic liver function tests. - Hematologic monitoring: conduct regular complete blood counts to detect myelosuppression. - Contraindications: avoid use in patients with severe immunodeficiency or uncontrolled infection. - Pregnancy and lactation: discontinue in women planning conception and advise against breastfeeding. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Methotrexate can interact with several drug classes, altering efficacy or toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal toxicity. - Penicillins and sulfonamides: may enhance myelosuppression. - Live vaccines: heightened risk of infection due to immunosuppression. - Other folate antagonists: additive toxic effects on bone marrow and liver.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect renal clearance of methotrexate. - Diuretics: can increase serum concentrations, requiring dose adjustment. - Oral contraceptives: reduced efficacy, advise alternative contraception. - Anticonvulsants (e.g., phenytoin): may lower methotrexate levels, affecting therapeutic response.